Viracept

ネルフィナビル。ビラセプト

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/07/30 15:13:54」(JST)

wiki en

[Wiki en表示]

Nelfinavir

Systematic (IUPAC) name
(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylphenyl)formamido]-4-(phenylsulfanyl)butyl]-decahydroisoquinoline-3-carboxamide
Clinical data
Trade names	Viracept
AHFS/Drugs.com	monograph
MedlinePlus	a697034
Licence data	US FDA:link
Pregnancy cat.	B (US)
Legal status	℞-only (US)
Routes	oral
Pharmacokinetic data
Bioavailability	Uncertain; improved by taking with food
Protein binding	>98%
Metabolism	Hepatic metabolism by CYP450 incl. CYP3A4
Half-life	3.5 - 5 hours
Excretion	Metabolites eliminated in faeces
Identifiers
CAS number	159989-64-7 Y
ATC code	J05AE04
PubChem	CID 64143
DrugBank	DB00220
ChemSpider	57718 Y
UNII	HO3OGH5D7I Y
KEGG	D08259 Y
ChEBI	CHEBI:7496 N
ChEMBL	CHEMBL1159655 N
NIAID ChemDB	028590
Chemical data
Formula	C32H45N3O4S
Mol. mass	567.784 g/mol
SMILES O=C(c1cccc(O)c1C)N[C@@H](CSc2ccccc2)[C@H](O)CN4[C@H](C(=O)NC(C)(C)C)C[C@@H]3CCCC[C@@H]3C4
InChI InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1 Y Key:QAGYKUNXZHXKMR-HKWSIXNMSA-N Y
Physical data
Melt. point	349.94 °C (662 °F)
N (what is this?)  (verify)

Nelfinavir (brand name Viracept) is an antiretroviral drug used in the treatment of the human immunodeficiency virus (HIV). Nelfinavir belongs to the class of drugs known as protease inhibitors (PIs) and like other PIs is generally used in combination with other antiretroviral drugs.

Nelfinavir mesylate (Viracept, formally AG1343) is a potent and orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor (Ki=2nM) and is widely prescribed in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection.

History

Nelfinavir was developed by Agouron Pharmaceuticals as part of a joint venture with Japan Tobacco. Agouron Pharmaceuticals was acquired by Warner Lambert in 1999 and is now a subsidiary of Pfizer. It is marketed in Europe by Hoffman-La Roche and elsewhere by ViiV Healthcare.

The U.S. Food and Drug Administration (FDA) approved it for therapeutic use on March 14, 1997, making it the twelfth approved antiretroviral. The initial product launched proved to be the largest "biotech launch" in the history of the pharmaceutical industry, achieving first full year sales exceeding $US335M. Agouron's patent on the drug will expire in 2014.

On the 6 June 2007, both the Medicines and Healthcare products Regulatory Agency and the European Medicines Agency put out an alert requesting the recall of any of the drug in circulation, because some batches may have been contaminated with potentially cancer-causing chemicals.

Pharmacology

Nelfinavir should be taken with food. The bioavailability of Nelfinavir is increased 2.5 to 5 times when taken with food. Taking the drug with food also decreases the risk of diarrhea as a side effect.

Mechanism of action

Nelfinavir is a protease inhibitor: it inhibits HIV-1 and HIV-2 proteases. HIV protease is an enzyme (an aspartate protease) which splits viral protein molecules into smaller fragments, and it is vital to both the replication of the virus within the cell, and also to the release of mature viral particles from an infected cell. Nelfinavir is a competitive inhibitor (2 nM) which is designed to bind tightly and is not cleaved due to the presence of a hydroxyl group as opposed to a keto group in the middle amino acid residue mimic, which would be otherwise S-phenylcysteine. All protease inhibitors bind to the protease, the precise mode of binding determines how the molecule inhibits the protease. The way Nelfinavir binds the enzyme may be sufficiently unique to reduce cross-resistance between it and other PIs. Also, not all PIs inhibit both HIV-1 and HIV-2 proteases.

Toxicity

Nelfinavir can produce a range of adverse side effects. Flatulence, diarrhea or abdominal pain are common (i.e. experienced by more than one in one hundred patients). Fatigue, urination, rash, mouth ulcers or hepatitis are less frequent effects (experienced by one in one thousand to one in one hundred patients). Nephrolithiasis, arthralgia, leukopenia, pancreatitis or allergic reactions may occur, but are rare (less than one in one thousand patients) .

Potential anti-cancer activity

Nelfinavir were under investigation, in 2009, for potential use as an anti-cancer agent. When applied to cancer cells in culture (in vitro), it can inhibit the growth of a variety cancer types and can trigger cell death (apoptosis). When Nelfinavir was given to laboratory mice with tumors of the prostate or of the brain, it could suppress tumor growth in these animals. In vitro tests showed it may work well with sorafenib

In the United States, several clinical trials were conducted in 2008 that sought to verify whether nelfinavir is effective as a cancer therapeutic agent in humans. In some of these trials, nelfinavir was used alone in monotherapy fashion, whereas in others it was combined with other modes of cancer therapy, such as well-established chemotherapeutic agents or radiation therapy.

In 2008 very good phase I results were obtained for locally advanced pancreatic ductal adenocarcinoma (a form of pancreatic cancer). The phase I trial (of nelfinavir with radiotherapy), on 12 patients with inoperable pancreatic cancer, showed a doubling of survival times, and six patients had tumor regression to the extent that they became operable. A phase II trial of 80 patients is starting.

Interactions

Nelfinavir's interaction profile is similar to that of other protease inhibitors. Most interactions occur at the level of the Cytochrome P450 isozymes 3A4 and CYP2C19, by which nelfinavir is metabolised.

See also

• HIV-1 protease
• Cremophor EL
• Castor oil

References

• Pai, VB; Nahata, MC (March 1999). "Nelfinavir mesylate: a protease inhibitor". The Annals of Pharmacotherapy 33 (3): 325–39. doi:10.1345/aph.18089. PMID 10200859. 
• Bardsley-Elliot, A; Plosker, GL (March 2000). "Nelfinavir: an update on its use in HIV infection". Drugs 59 (3): 581–620. doi:10.2165/00003495-200059030-00014. PMID 10776836. 

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. HIV薬剤耐性検査の解釈についての手引 primer on interpretation of hiv drug resistance testing
• 2. 腎機能不全または肝機能不全を有する成人における抗レトロウイルス剤の用量調整 dose modification of antiretroviral agents in adults with renal or hepatic dysfunction
• 3. HIV-2感染の治療 treatment of hiv 2 infection
• 4. 未治療HIV感染患者のための抗レトロウイルス療法の選択 selecting antiretroviral regimens for the treatment naive hiv infected patient
• 5. ヒトヘルペスウイルス8感染の診断および抗ウイルス療法 diagnosis and antiviral therapy of human herpesvirus 8 infection

English Journal

• Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer.

• Kattel K1, Evande R2, Tan C3, Mondal G1, Grem JL2, Mahato RI1.
• British journal of clinical pharmacology.Br J Clin Pharmacol.2015 Aug;80(2):267-75. doi: 10.1111/bcp.12620. Epub 2015 Jun 11.
• AIM: This study evaluated the influence of CYP2C19 polymorphisms on the pharmacokinetics of nelfinavir and its metabolite M8 in patients with pancreatic cancer.METHODS: Nelfinavir was administered orally to patients for over 10 days. The plasma concentrations of nelfinavir and M8 were measured by HP
• PMID 25752914

• Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway.

• Xiang T1, Du L2, Pham P2, Zhu B3, Jiang S4.
• Cancer letters.Cancer Lett.2015 Aug 1;364(1):79-88. doi: 10.1016/j.canlet.2015.04.027. Epub 2015 Apr 29.
• HIV protease inhibitors (HIV-PIs) are a class of antiretroviral drugs designed to target the viral protease. Strikingly, these drugs have also been reported to possess antitumor effect. In this study, we evaluated the activity of one HIV-PI, Nelfinavir, against human cervical cancer cells. We found
• PMID 25937300

• Delayed HIV detection among infants exposed to postnatal antiretroviral prophylaxis during breastfeeding.

• King CC1, Kourtis AP, Persaud D, Nelson JA, Ziemniak C, Hudgens MG, Tegha G, Chasela CS, Jamieson DJ, van der Horst CM.
• AIDS (London, England).AIDS.2015 Jul 3. [Epub ahead of print]
• OBJECTIVE: The objective of this study is to determine whether detection of HIV infection was delayed in infants exposed to antiretroviral prophylaxis to prevent HIV transmission during breastfeeding.DESIGN: The Breastfeeding, Antiretrovirals and Nutrition (BAN) study was a randomized trial of 2369
• PMID 26153671

Related Links

• Viracept | Define Viracept at Dictionary.com

What Is Dosage Of Viracept Dosage? Dictionary.com Word FAQs Dictionary.com presents 366 FAQs, incorporating some of the frequently asked questions from the past with newer queries. Differences Etymology/Origins Spelling ...

• Viracept - Definition of Viracept

Menu Dictionary YD Original Websters AHD Ologies Business Computer Culture Images/Pictures Invest Law Medical Phrases/Idioms Science See in a sentence Thesaurus Quotes Teaching & Learning Education ESL Grammar

Related Pictures

---

★リンクテーブル★

リンク元

「ネルフィナビル」

「ネルフィナビル」

　　[★]

英

nelfinavir, NFV

化

メシル酸ネルフィナビル nelfinavir mesilate

商

ビラセプト Viracept